OncoMatch/Clinical Trials/NCT06613269
68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.
Is NCT06613269 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including 68Ga-NY104 PET/CT and 18F-FDG PET/CT for clear cell renal cell carcinoma.
Treatment: 68Ga-NY104 PET/CT · 18F-FDG PET/CT · Systemic therapy — Radiation therapy (RT) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccRCC). Current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastatic/recurrent ccRCC. CAIX is a highly sensitive and specific biomarker expressed on ccRCC and in previous studies the investigators have shown excellent diagnostic efficacy of 68Ga-NY104, a CAIX-targeted PET tracer, in patients with metastatic ccRCC. In this study, the investigators aim to investigate the effect of 68Ga-NY104, and 18F-FDG PET/CT guided RT combining standard systemic therapy in patients with metastatic ccRCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify